ArticleiScience2026
A multicenter multimodel habitat radiomics model for predicting immunotherapy response in advanced NSCLC.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A robust predictive biomarker is critical for identifying patients with NSCLC who may benefit from immunotherapy. This study developed a CT-based habitat model using 590 advanced NSCLC cases. The model was constructed in contrast-enhanced CT images and validated on an independent cohort with non-contrast CT. Tumor volumes were segmented into three subregions via K-means clustering. Radiomic features were extracted from each habitat and used to build predictive models with six machine learning classifiers. The ExtraTrees-based habitat model demonstrated superior predictive performance in the test cohort (AUC = 0.814). Compared to traditional radiomics, 3D deep learning, clinical, and PD-L1 expression models, the habitat model maintained strong predictive advantages, enabling efficient prediction of immunotherapy benefit and aiding in the identification of suitable patients for personalized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.